Moreover, we also showed that the MCM10 inhibitors Suramin and its analogues (NF157, NF546, and PPADS) can be used as potential anti‐cancer agents for ESCC, but are warranted to deconstruct the precise mechanisms and effective targets of these drugs before its clinical use. Here, MCM10 is linked to cancer.